Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04697160
Status:
COMPLETED
Last Update Posted:
2021-10-20
First Post:
2020-12-23
Brief Title:
Observational Retrospective Cohort Study of Systemic Therapies for RR DLBCL
Sponsor:
MorphoSys AG
Organization:
MorphoSys AG
Study Overview
Official Title:
An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma RR DLBCL to Compare Outcomes to Those From Tafasitamab Lenalidomide in the L-MIND Study
Status:
COMPLETED
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RE-MIND2
Brief Summary:
To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCNESMO guideline listed regimens administered in routine clinical care
Detailed Description:
This retrospective observational cohort study aims to generate a historical control consisting of RR DLBCL patients who received currently guideline recommended therapies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None